Commercialization License. Subject to the terms and conditions of this Agreement, including Section 5.2.3 and [Section 9.3.2], [[Organization A:Organization]] hereby grants to CRISPR a non-exclusive license under Licensed [[Organization A:Organization]] Technology (as defined below) to Research, Develop, Manufacture and Commercialize Product Candidates and Products, whether such Product Candidates and Products are conceived, discovered or advanced in the Research Program or in continued research and development by or on behalf of CRISPR after termination of this Agreement, for use in the Field, which license shall be exercisable only if and when [[Organization A:Organization]] becomes the Granting Party under [Section 9.3.2(a)] and shall terminate automatically if and when CRISPR becomes the Granting Party under [Section 9.3.2(a)]. Except as otherwise provided in [Section 9.3.2(f)], such license shall be royalty-free and fully-paid. After the license becomes exercisable, such license shall be sublicenseable solely to the recipient of a sublicense by CRISPR of intellectual property Controlled by CRISPR that pertains to such Product Candidates and Products. Notwithstanding anything to the contrary herein, to the extent that any [[Organization A:Organization]] Technology is Controlled by [[Organization A:Organization]] pursuant to the terms of any Third Party agreement, any such license shall be subject to any applicable terms and conditions of such Third Party agreement, including any payment obligations to such Third Party that would arise from CRISPR’s exercise of a license under such [[Organization A:Organization]] Technology. “Licensed [[Organization A:Organization]] Technology” means such [[Organization A:Organization]] Technology as is reasonably necessary or useful to Research, Develop, Manufacture and Commercialize Product Candidates and Products in the Field.

Commercialization License. Subject to the terms and conditions of the Agreement and this Exhibit, Janssen hereby grants, and shall cause its Affiliates to grant, to Fate, during the Profit Share Term for each Profit Share Product, a co-exclusive (with Janssen), non-transferable (except as permitted under [Section 17.4] of the Agreement) license under the Janssen Profit Share Product Patents, Janssen Profit Share Product Know-How and the Product Trademarks, and sublicense under the Fate Product Patents and Fate Product Know-How exclusively licensed to Janssen under [Section 5.1.2] of the Agreement, to sell, offer to sell, have sold, import and otherwise Commercialize the Profit Share Product in the Field in the U.S.

Commercialization License. Subject to the terms and conditions of this Agreement including Section 5.1.3 and [Section 9.3.2, CRISPR]R] hereby grants to [[Organization A:Organization]] a non-exclusive license under Licensed CRISPR Technology (as defined below) to Research, Develop, Manufacture and Commercialize Product Candidates and Products, whether such Product Candidates and Products are conceived, discovered or advanced in the Research Program or in continued research and development by or on behalf of [[Organization A:Organization]] after termination of this Agreement, for use in the Field, which license shall be exercisable only if and when CRISPR becomes the Granting Party under [Section 9.3.2(a)] and shall terminate automatically if and when [[Organization A:Organization]] becomes the Granting Party under [Section 9.3.2(a)]. Except as otherwise provided in [Section 9.3.2(f)], such license shall be royalty-free and fully-paid. After the license becomes exercisable, such license shall be sublicenseable solely to the recipient of a license by [[Organization A:Organization]] of intellectual property Controlled by [[Organization A:Organization]] that pertains to such Product Candidates and Products. Notwithstanding anything to the contrary herein, to the extent that any CRISPR Technology is Controlled by CRISPR pursuant to the terms of any Third Party agreement, any such license shall be subject to any applicable terms and conditions of such Third Party agreement, including any payment obligations to such Third Party that would arise from [[Organization A:Organization]]’s exercise of a license under such CRISPR Technology. “Licensed CRISPR Technology” means such CRISPR Technology as is reasonably necessary or useful to Research, Develop, Manufacture and Commercialize Product Candidates and Products in the Field.

Commercialization License. Subject to the terms and conditions of this Agreement, Arrowhead hereby grants to Janssen an exclusive (even as to Arrowhead, except to the extent Arrowhead expressly retains or is expressly granted back rights under this Agreement), worldwide license, with the right to sublicense in accordance with [Section 2.1.4], under the Arrowhead Intellectual Property, to Commercialize and have Commercialized, offer for sale and sell, and have offered for sale and sold, Licensed Constructs and Licensed Products, for use in the Field in the Territory, and to make, have made, use, have used, and import and have imported Licensed Constructs and Licensed Products for such purposes. The license rights granted under this [Section 2.1.2] shall continue, on a product-by-product and country-by-country basis, throughout the Term hereof, subject to the termination provisions under Article XV.

Commercialization License. Medytox hereby grants AEON and its Affiliates a non-exclusive, royalty bearing, irrevocable (except pursuant to Sections 9.2 or 9.3 or the occurrence of the circumstances described in Section 13.6) right and license to the Licensed Rights to Commercialize and obtain or maintain the Marketing Authorization and all Regulatory Materials related to any Licensed Product in the Territory (the “Commercialization License”).

Commercialization License. Subject to the terms and conditions of this Agreement, Nektar hereby grants, and shall cause its Affiliates to grant, to BMS (and BMS hereby accepts) a co-exclusive (with Nektar), worldwide, non-transferable (except as provided in [Section 17.12]), royalty-free (with the right to sublicense solely pursuant to the terms of and subject to the limitations of Section 11.3) license under Nektar Asset Patent Rights, Nektar Background Patent Rights, Nektar Technology, and Nektar Regulatory Documentation, in each case in respect of the foregoing, solely:

Commercialization License. Abbott hereby grants to Enanta during the Term a co-exclusive (together with Abbott), royalty-free, fully paid license, without the right to grant sublicenses, under Abbott Technology, Abbott Patent Rights and Abbott’s interest in Joint Technology and Joint Patent Rights for the sole purpose of Developing and Commercializing Co-Developed Products in the Field in the Co-Development Territory.

Commercialization License. Subject to the terms and conditions of this Agreement, BMS hereby grants, and shall cause its Affiliates to grant, to Nektar (and Nektar hereby accepts) a non-exclusive, worldwide, non-transferable (except as provided in [Section 17.12]), royalty-free (with the right to sublicense solely pursuant to the terms of and subject to the limitations of Section 11.3) license under BMS Asset Patent Rights, BMS Background Patent Rights, BMS Technology, and BMS Regulatory Documentation, in each case in respect of the foregoing, solely to Commercialize (but not to do any of the following: obtain pricing or reimbursement approvals; sell; offer for sale; have sold; or offer to have sold) the Nektar Compounds and Products, in Monotherapies (but only Nektar Compounds and Products) and Combined Therapies, in the Field and in the Territory.

Commercialization License. Abbott shall have the right to grant sublicenses under the license granted to it under Section 8.2.1 to any Affiliate of Abbott and to any Third Party with respect to any Product, other than any Co-Developed Product in the Co-Development Territory after which time Enanta has exercised its Co-Development and Profit Share Option with respect to such Co-Developed Product; provided, that: # it shall be a condition of any such sublicense that such Sublicensee agrees to be bound by all terms of this Agreement applicable to the Development of Candidates and the Commercialization of Products in the Field in the Territory (including, without limitation, Article 7); # Abbott shall provide written notice to Enanta of any such proposed sublicense at least thirty (30) days prior to such execution; and # Abbott shall not be relieved of any of its obligations pursuant to this Agreement as a result of such sublicense.

Licensor grants to Licensee a royalty-bearing exclusive license under the Patent Rights to develop, manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field in the Territory and/or to perform Licensed Services in the Field in the Territory.